Contact Us
Drug Search Results
More Filters [+]

LY-2300559

Alternative Names: ly-2300559, ly2300559, ly 2300559
Latest Update: 2018-09-12
Latest Update Note: Clinical Trial Update

Product Description

LY2300559 is a dual metabotropic glutamate receptor 2 (mGluR2) positive allosteric modulator and cysteinyl leukotriene receptor 1 (CysLTR1) antagonist. Eli Lilly was developing LY2300559 for the prevention of migraine (Sourced from: https://drugs.ncats.io/drug/Z572ZBT8XL)

Mechanisms of Action: mGLUR2 Modulator,CysLT Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LY-2300559

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Headache Disorders|Migraine Disorders

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
I1N-MC-CDBE

P2

Terminated

Headache Disorders|Migraine Disorders

2012-04-01

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions